Ovarian Cancer

Study in Primary Treatment of Cancer Commences

Published in Cancer Weekly, December 19th, 2000

BICO, Inc. (BIKO), Pittsburgh, Pennsylvania, and a subsidiary of ViaCirQ, Inc., announced that it has commenced a study with Wake Forest University Baptist Medical Center utilizing the ThermoChem-HT System and related disposables to deliver intraperitoneal hyperthermia (IPH) in combination with cytoreductive surgery and chemotherapy in the primary treatment of ovarian cancer.

Ovarian cancer is the leading cause of death in the United States from gynecologic malignancies. There are approximately 26,600 new cases and 14,500 deaths annually.

The majority of patients have advanced disease at the time of diagnosis, which remains confined to the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-12-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry